<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833114</url>
  </required_header>
  <id_info>
    <org_study_id>Pola-R-ICE</org_study_id>
    <secondary_id>MO40599 / GLA 2017-R2</secondary_id>
    <nct_id>NCT04833114</nct_id>
  </id_info>
  <brief_title>Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <acronym>Pola-R-ICE</acronym>
  <official_title>Open-label, Prospective Phase III Clinical Study to Compare Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) With Rituximab, Ifosfamide, Carboplatin and Etoposide (R-ICE) Alone as Salvage Therapy in Patients With Primary Refractory or Relapsed Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus&#xD;
      rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide,&#xD;
      carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary&#xD;
      refractory or relapsed diffuse large B-cell lymphoma (DLBCL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as an international, multicenter, open-label, two-arm, prospective&#xD;
      phase III study to compare the treatment of polatuzumab vedotin plus rituximab, ifosfamide,&#xD;
      carboplatin and etoposide (Pola-R-ICE) with the combination of rituximab, ifosfamide,&#xD;
      carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary&#xD;
      refractory or relapsed DLBCL.&#xD;
&#xD;
      The study will involve study sites in Germany, UK, Spain, and Austria. It is planned to&#xD;
      include 324 patients who will be randomized 1:1 to receive either treatment in the&#xD;
      experimental arm (Pola-R-ICE) or in the standard arm (R-ICE) to end up with 308 evaluable&#xD;
      subjects for the randomized part of the trial. Further 10 patients will be treated with&#xD;
      Pola-R-ICE during the safety run-in phase.&#xD;
&#xD;
      The study consists of a screening/inclusion visit, three chemotherapy cycles, an end-of -&#xD;
      treatment visit (EoT), and follow-up visits. For each subject, the total duration of the&#xD;
      study will be approximately 3 months of treatment plus at least 21 months follow-up. The&#xD;
      study will end when the last included patient will have passed the last follow-up visit&#xD;
      (LPLFU). For the study as a whole, the primary outcome will be evaluated when the last&#xD;
      included patient will have completed the 21 months follow-up period or has left the study&#xD;
      prematurely.&#xD;
&#xD;
      For the study as a whole, the primary outcome will be evaluated when the last included&#xD;
      patient will have completed the 21 months follow-up period or has left the study prematurely.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the event-free survival of patients with DLBCL at first progression and the occurrence of any of the following events:</measure>
    <time_frame>Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up)</time_frame>
    <description>Failure to achieve sufficient response in PET-CT (Deauville score 3 or less) at end of study treatment (metabolic CR)&#xD;
Disease progression (PD)&#xD;
Start of additional unplanned anti-tumor treatment (radiation therapy allowed)&#xD;
Relapse after achieving CR&#xD;
Death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the rate of metabolic complete response.</measure>
    <time_frame>Day of randomization until end weeks 12 treatment.</time_frame>
    <description>Number of complete remissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the partial response rate.</measure>
    <time_frame>Day of randomization until end of 12 weeks treatment.</time_frame>
    <description>Number of partial responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the overall response rate.</measure>
    <time_frame>Day of randomization until end of 12 weeks treatment.</time_frame>
    <description>Number of complete and partial responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment duration of response.</measure>
    <time_frame>Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up)</time_frame>
    <description>Time from documentation of tumor response to disease progression or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the rate of progressive disease.</measure>
    <time_frame>Day of randomization until end of 12 weeks treatment.</time_frame>
    <description>Number of progressive diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of disease relapse.</measure>
    <time_frame>Day of randomization until end of 12 weeks treatment.</time_frame>
    <description>Number of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of progression free survival.</measure>
    <time_frame>Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up)</time_frame>
    <description>Occurence of disease progression, relapse or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of overall survival.</measure>
    <time_frame>Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the rate of patients proceeding to transplantation.</measure>
    <time_frame>Day of randomization until week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the rate of patients with non-relapse mortality.</measure>
    <time_frame>Day of randomization until end of follow up (12 weeks treatment and at least 21 months follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the frequency of adverse and serious adverse events including the incidence and duration of the adverse events neutropenia and thrombocytopenia with grade 4.</measure>
    <time_frame>Day of Randomization until 28 days after start of last cycle or start of further therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the number of patients with treatment-related death.</measure>
    <time_frame>Day of Randomization until up week 12 or 2 months after week 12 but before start of further therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the number of patients with occurence of second malignancies</measure>
    <time_frame>Day of Randomization until Day of randomization until end of follow up (at least 21 months follow up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the protocol adherence by the rate and duration of chemotherapy cycles patients received.</measure>
    <time_frame>Day of Randomizaton until week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the cumulative and relative dose of each IMP( ifosfamide, carboplatin and etoposide, rituximab and of the polatuzumab vedotin) by quantitative measurement.</measure>
    <time_frame>Day of Randomizaton until week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the change in health related quality of life by generic questionnaire.</measure>
    <time_frame>Day of Randomization until weeks 12 and months 3 and 12 in follow up.</time_frame>
    <description>Scale scores to be obtained for the multi-items scales. Range in score from 0 to 100. A high scale score represents a higher response level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the change in health related quality of life by five-item questionnaire.</measure>
    <time_frame>Day of Randomization until weeks 12 and months 3 and 12 in follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment visual analogue scale to measure health state.</measure>
    <time_frame>Day of Randomization until weeks 12 and months 3 and 12 in follow up</time_frame>
    <description>This scale is provided with numbers from 0 to 100.100 is the best health state and 0 (zero) is the worst health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional assessment of the cancer therapy-lymphoma by general questions and specific questions for lymphoma.</measure>
    <time_frame>Day of Randomization until weeks 12 and months 3 and 12 in follow up.</time_frame>
    <description>Assessment how lymphoma-specific symptoms impact quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Relapsed Diffuse Large B-cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental Arm: Pola-R-ICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of standard chemotherapy with polatuzumab vedotin (Pola-R-ICE) Application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arm: R-ICE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional treatment with rituximab, ifosfamide, carboplatin and etoposide (R-ICE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab Vedotin</intervention_name>
    <description>Polatuzumab vedotin 1.8 mg/kg will be administered intravenously on Day 1 of each 21-day cycle for up to 3 cycles.</description>
    <arm_group_label>Experimental Arm: Pola-R-ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mabthera</intervention_name>
    <description>Rituximab (Mabthera/Rituxan®) will be administered as per local practice at a dose of 375 mg/m2 intravenously on Day 1 of each 21-day cycle for up to 3 cycles.</description>
    <arm_group_label>Experimental Arm: Pola-R-ICE</arm_group_label>
    <arm_group_label>Standard Arm: R-ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide 5000 mg/m² will be administered i.v. over a 24 hr period starting on cycle Day 2.</description>
    <arm_group_label>Experimental Arm: Pola-R-ICE</arm_group_label>
    <arm_group_label>Standard Arm: R-ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 max 800 mg will be administered i.v. on cycle Day 2.</description>
    <arm_group_label>Experimental Arm: Pola-R-ICE</arm_group_label>
    <arm_group_label>Standard Arm: R-ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 100 mg/m² will be administered i.v. on cycle Days 1, 2 and 3.</description>
    <arm_group_label>Experimental Arm: Pola-R-ICE</arm_group_label>
    <arm_group_label>Standard Arm: R-ICE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The informed consent form must be signed before any study specific tests or procedures&#xD;
             are done&#xD;
&#xD;
          2. Adult male and female patients ≥18 years (≥16 years in the UK*) at the time of&#xD;
             inclusion in the study (* In the UK an &quot;adult&quot; means a person who has attained the age&#xD;
             of 16 years, according to The Medicines for Human Use (Clinical Trials) Regulations&#xD;
             2004, Part 1 Point 2.)&#xD;
&#xD;
          3. Ability to understand and follow study-related instructions&#xD;
&#xD;
          4. Risk group: All patients with one of the following histologically defined entities:&#xD;
             Histological diagnosis of primary refractory or relapsed aggressive B-cell non-Hodgkin&#xD;
             lymphoma (B-NHL), confirmed by a biopsy of involved nodal or extranodal site. Patients&#xD;
             with any of the following histologies can be included:&#xD;
&#xD;
               -  DLBCL not otherwise specified (NOS)&#xD;
&#xD;
               -  T-cell/histiocyte-rich large B-cell lymphoma&#xD;
&#xD;
               -  Primary cutaneous DLBCL, leg type&#xD;
&#xD;
               -  Epstein-Barr virus (EBV)-positive DLBCL, NOS&#xD;
&#xD;
               -  DLBCL associated with chronic inflammation&#xD;
&#xD;
               -  Primary mediastinal (thymic) large B-cell lymphoma&#xD;
&#xD;
               -  High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements&#xD;
&#xD;
               -  High-grade B-cell lymphoma, NOS&#xD;
&#xD;
             Refractory disease is defined as no complete remission to first line therapy; subjects&#xD;
             who are intolerant to first line therapy are excluded. Three groups of patients are&#xD;
             eligible:&#xD;
&#xD;
               -  Progressive disease (PD) as best response to first line therapy (biopsy not&#xD;
                  mandatory if diagnostic sample available).&#xD;
&#xD;
               -  Stable disease (SD) as best response after at least 4 cycles of first line&#xD;
                  therapy (e.g., 4 cycles of R-CHOP) (biopsy not mandatory if diagnostic sample&#xD;
                  available).&#xD;
&#xD;
               -  Partial response (PR) as best response after at least 6 cycles, and biopsy-proven&#xD;
                  residual disease or disease Progression after the partial response.&#xD;
&#xD;
             Relapsed disease is defined as complete remission to first line therapy followed by&#xD;
             biopsy proven disease relapse.&#xD;
&#xD;
          5. Performance Status ECOG 0-2 at time of randomization or ECOG 3 at screening if this is&#xD;
             DLBCL-related and has improved to ECOG 2 or less with a 7-day steroid treatment during&#xD;
             the screening Phase (e.g. 1 mg/kg prednisone).&#xD;
&#xD;
          6. Information on all 5 International Prognostic Index (IPI) factors&#xD;
&#xD;
          7. Staging (PET-CT based-staging according to Lugano criteria 2014). Patients must have&#xD;
             PET-positive lesions.&#xD;
&#xD;
          8. Subjects must have received adequate first line therapy including at a minimum: i)&#xD;
             anti-CD20 monoclonal antibody unless Investigator determines that tumor is CD20&#xD;
             negative, and ii) an anthracycline containing chemotherapy Regimen&#xD;
&#xD;
          9. Intent to proceed to high-dose therapy (HDT) and stem cell transplantation (SCT) if&#xD;
             response to second line therapy&#xD;
&#xD;
         10. Adequate hematological function, as defined by: hemoglobin ≥ 8 g/dL, absolute&#xD;
             neutrophil count (ANC) ≥ 1.0 x 109/L OR ≥ 0.5 x 109/L if neutropenia is attributable&#xD;
             to underlying disease and before the administration of steroids, and platelet count ≥&#xD;
             75 x 109/L OR ≥ 50 x 109/L if thrombocytopenia is attributable to Underlying disease&#xD;
&#xD;
         11. Women of childbearing potential must have a negative pregnancy test result within 7&#xD;
             days prior to the first study drug Administration&#xD;
&#xD;
         12. For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive measures, and agreement to refrain from&#xD;
             donating eggs&#xD;
&#xD;
         13. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agreement to refrain from donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) Serious accompanying disorder leading to impaired organ function causing significant&#xD;
        clinical problems and reduced life expectancy of less than 3 months. In particular,&#xD;
        patients with the following organ dysfunction caused by accompanying disorders are to be&#xD;
        excluded:&#xD;
&#xD;
          -  Heart failure with left ventricular ejection fraction (LVEF) &lt; 45%&#xD;
&#xD;
          -  Impaired pulmonary function with vital capacity (VC) or forced expiratory volume&#xD;
             (FEV1) &lt; 50% of normal (only in case of history of significant pulmonary disease)&#xD;
&#xD;
          -  Impaired renal function with glomerular filtration rate (GFR) &lt; 50 mL/min (calculated)&#xD;
&#xD;
          -  Impaired liver function with alanine aminotransferase (ALAT), aspartate&#xD;
             aminotransferase (ASAT) or Bilirubin &gt; 1.5 x upper limit of normal (ULN). If elevation&#xD;
             is caused by the disease, threshold of 2.5 x ULN is accepted&#xD;
&#xD;
          -  Peripheral neuropathy &gt; Grade II (2) Human immunodeficiency virus (HIV)-positivity&#xD;
             with detectable viral load and/or a CD4+ count below 0.3/nL&#xD;
&#xD;
             (3) Hepatitis B and C as defined by seropositivity (HBsAG and anti HBe/ anti HBc;&#xD;
             anti-Hc); in case of false positive serology (transfused antibodies) negative&#xD;
             PCR-results will allow patient inclusion. Patients with occult or prior HBV infection&#xD;
             (defined as negative HBsAg and positive hepatitis B core antibody [HBcAb]) may be&#xD;
             included if HBV DNA is undetectable, provided that they are willing to undergo DNA&#xD;
             testing on Day 1 of every cycle and monthly for at least 12 months after the last&#xD;
             cycle of study Treatment&#xD;
&#xD;
             (4) Known active bacterial, viral, fungal, mycobacterial, parasitic, or other&#xD;
             infection (excluding fungal infections of nail beds) at study inclusion or any&#xD;
             unresolved major episode of infection (as evaluated by the investigator) within 1 week&#xD;
             prior to Cycle 1 Day 1&#xD;
&#xD;
             (5) Patients with suspected or latent tuberculosis. Latent tuberculosis needs to be&#xD;
             confirmed by positive interferon-gamma release Assay&#xD;
&#xD;
             (6) Primary or secondary central nervous system (CNS) lymphoma at the time of&#xD;
             recruitment&#xD;
&#xD;
             (7) Richter's transformation or prior chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
             (8) Vaccination with a live vaccine within 4 weeks prior to Treatment&#xD;
&#xD;
             (9) Recent major surgery (within 6 weeks before the start of Cycle 1 Day 1) other than&#xD;
             for diagnosis&#xD;
&#xD;
             (10) Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive&#xD;
             therapy, or any investigational agent for the purposes of treating cancer within 2&#xD;
             weeks prior to Cycle 1 Day 1&#xD;
&#xD;
             (11) Received more than one line of therapy for DLBCL&#xD;
&#xD;
             (12) Received polatuzumab vedotin as part of the first line therapy&#xD;
&#xD;
             (13) Any other diseases, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
             (14) Ongoing treatment or study procedures within any other Investigational Medicinal&#xD;
             Product (IMP) clinical trial with the exception of follow-up. In case of a preceding&#xD;
             clinical trial, last application of the respective IMP(s) must have been done more&#xD;
             than five elimination half-lives before start of study medication in this trial.&#xD;
&#xD;
             (15) History of severe allergic or anaphylactic reactions to human, humanized,&#xD;
             chimeric, or murine monoclonal antibodies&#xD;
&#xD;
             (16) History of hypersensitivity to any of the study drugs or their ingredients or to&#xD;
             drugs with similar structure&#xD;
&#xD;
             (17) Contraindications according to the Investigator´s Brochure (IB) of polatuzumab&#xD;
             vedotin or the local Summary of Product Characteristics (SmPCs) of the used rituximab,&#xD;
             ifosfamide, carboplatin or etoposide products&#xD;
&#xD;
             (18) Criteria which in the opinion of the investigator preclude participation for&#xD;
             scientific reasons, for reasons of compliance, or for reasons of the subject's Safety&#xD;
&#xD;
             (19) Pregnancy or breastfeeding, or intending to become pregnant during the study or&#xD;
             within 12 months after the last dose of study drug&#xD;
&#xD;
             (20) Close affiliation with the investigator (e.g. a close relative) or persons&#xD;
             working at the study site&#xD;
&#xD;
             (21) Subject is an employee of the sponsor or involved Contract Research Organization&#xD;
&#xD;
        At study inclusion, any organ impairment due to lymphoma infiltration is NOT regarded as an&#xD;
        exclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Glaß, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Pigur, Dr.</last_name>
    <phone>0049 351 25933</phone>
    <phone_ext>192</phone_ext>
    <email>polarice@g-wt.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Med Campus III, Univ.-Klinik für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH Meduni Wien Universitätsklinik für Innere Medizin I:</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen Abteilung für Innere Medizin IV</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum RWTH-Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev.Diakonie-Krankenhaus gemeinnützige GmbH</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital Dortmund</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Onkologie, Hämatologie und Palliativmedizin</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georg-August-Universität Göttingen Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unversitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Universitätsklinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Carretera De Valdemossa</city>
        <state>Palma</state>
        <zip>79</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>Donostia</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Català d'oncologia de L'Hospitalet (ICO-L'Hospitalet)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hopsital</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University London College Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

